Clinical Trial Update: The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) [Phase 2]

View source ↗

Summary

Phase 2 EndoBARR trial evaluating endometrial cancer with bevacizumab, atezolizumab, and rucaparib has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Uterine Carcinosarcoma

Drugs mentioned

• Atezolizumab (Tecentriq) (atezolizumab)
• Bevacizumab (Avastin) (bevacizumab)
• Rucaparib (Rubraca) (Rucaparib)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Endometrial Cancer, Uterine Carcinosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2025-05-30